Headquartered in San Diego, CA Fiscal year ends December NASDAQ: ERAS erasca.com
Erasca, Inc. is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline centers on ERAS-0015, a potential best-in-class pan-RAS molecular glue currently in Phase 1 trials across pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal cancer (in combination with panitumumab), and ERAS-4001, a potential first-in-class pan-KRAS inhibitor in Phase 1 testing. The company was co-founded by pioneers in precision oncology and RAS targeting and is advancing toward multiple potentially registration-enabling trials in high-unmet-need KRAS-mutant cancers. Erasca trades on Nasdaq under the ticker ERAS and is pre-revenue, funding operations through public equity offerings. Updated
Clinical-stage biotech is one of the few corners of the market where a sub-$30 share price genuinely matters: small-cap oncology names can re-rate violently around a single Phase 3 readout or FDA…
Wall Street is turning constructive on three clinical-stage biotechs simultaneously, each sitting at the edge of a binary catalyst. The analyst calls on uniQure (NASDAQ:QURE), Syndax Pharmaceuticals (NASDAQ:SNDX), and Erasca (NASDAQ:ERAS) share…
A biotech stock rallying on encouraging trial results prompted insider buying and selling. A specialty retailer and others saw insider buying too.
Erasca, Inc. is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
The Wall Street consensus 12-month price target for ERAS is $24.11.
